Winning Wednesday: Big Tide Summit
SAVANNAH, Ga. (WSAV) — The saying goes, tomorrow belongs to those who prepare for it.
One man knows that all too well, and he is leveling up with his knowledge and passion to power our future.
Robert Gould, founder of the Big Tide Summit, is back with WSAV's Tina Tyus-Shaw for part two.
We want you to know that it's not too late to get involved. If you've been around young people, you know their energy, their tenacity, their resilience, and their hope for the future.
Help us lift them by supporting the Go Big Career Brunch. Click here to buy tickets.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Luminar Technologies, Inc. (LAZR) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Luminar Technologies, Inc. (LAZR) closed the latest trading day at $3.27, indicating a -5.49% change from the previous session's end. The stock's change was less than the S&P 500's daily loss of 0.27%. Shares of the company witnessed a loss of 23.62% over the previous month, trailing the performance of the Auto-Tires-Trucks sector with its gain of 5.86%, and the S&P 500's gain of 6.9%. Analysts and investors alike will be keeping a close eye on the performance of Luminar Technologies, Inc. in its upcoming earnings disclosure. On that day, Luminar Technologies, Inc. is projected to report earnings of -$1.19 per share, which would represent year-over-year growth of 55.93%. Meanwhile, our latest consensus estimate is calling for revenue of $16.72 million, up 1.64% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.29 per share and revenue of $86.64 million, which would represent changes of +53.57% and +14.91%, respectively, from the prior year. Investors should also pay attention to any latest changes in analyst estimates for Luminar Technologies, Inc. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 21.36% higher within the past month. Luminar Technologies, Inc. is currently sporting a Zacks Rank of #2 (Buy). The Automotive - Original Equipment industry is part of the Auto-Tires-Trucks sector. This industry currently has a Zacks Industry Rank of 131, which puts it in the bottom 47% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Luminar Technologies, Inc. (LAZR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Hispanic Chamber of Commerce promotes local Hispanic businesses
SAVANNAH, Ga. (WSAV)– The Hispanic community has grown of the past few years, and the Metropolitan Savannah Area Hispanic Chamber of Commerce president said it will continue to grow. The Hispanic Chamber said it's their mission to provide a voice for the local Savannah businesses. They also don't only serve the Hispanic community, but also the non-Hispanic community by bridging the gap between them. 'The Hispanic Chamber is basically, people who don't know anything about Hispanics and people who know about Hispanics or are Hispanic and bringing them together,' Hispanic Chamber President Alfonso Ribot said. Ribot said that the diverse community is what the Savannah area needs, and the Hispanic businesses have something unique that everyone can enjoy. 'I know we're talking about some of the things that are happening out there in which businesses are closing, but one of the things that Hispanic businesses are doing is food,' Ribot said. 'Our culture, our way of treating people is appealing not just to Hispanics.' Ribot said Hispanic business owners are more prone to stick to the business because it's like a family and that business needs to be promoted. 'If you are non-Hispanic, Hispanic and you are able lease patronize Hispanic businesses and anyone that has that little sign on the door that says Hispanic Chamber of Commerce member, come in you're going to love it,' Ribot said. The Metropolitan Savannah Area Hispanic Chamber of Commerce said they welcome anyone to join the chamber. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
